 Venlafaxine Hydrochloride
"Venlafaxine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.
| Descriptor ID |
D000069470
|
| MeSH Number(s) |
D02.033.415.510.500.901 D02.092.471.683.948 D02.455.426.392.368.367.318.750 D10.289.510.500.901
|
| Concept/Terms |
Venlafaxine Hydrochloride- Venlafaxine Hydrochloride
- Hydrochloride, Venlafaxine
- Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
- 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl
Wy 45030- Wy 45030
- Wy-45030
- Wy45030
- Wy-45,030
- Wy 45,030
- Wy45,030
Effexor- Effexor
- Trevilor
- Vandral
- Efexor
|
Below are MeSH descriptors whose meaning is more general than "Venlafaxine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Venlafaxine Hydrochloride".
This graph shows the total number of publications written about "Venlafaxine Hydrochloride" by people in this website by year, and whether "Venlafaxine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Venlafaxine Hydrochloride" by people in Profiles.
-
Brajcich MR, Palau MA, Messer RD, Murphy ME, Marks J. Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Pediatrics. 2021 02; 147(2).
-
Lyon C, Mullen R, Deffenbacher B, Reed A, Nashelsky J. Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms? J Fam Pract. 2018 03; 67(3):175-176.
-
VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015 Feb; 40(1):1-6.
-
Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, Ensrud KE, Freeman EW, Joffe H, Sternfeld B, Reed SD, Sherman S, Sammel MD, Kroenke K, Larson JC, Lacroix AZ. Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network. Menopause. 2014 Jan; 21(1):45-58.
-
Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med. 2007 Sep; 8 Suppl 2:S43-9.
-
Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry. 2005 Feb 01; 57(3):220-8.
-
Silk KR, Yager J. Suggested guidelines for e-mail communication in psychiatric practice. J Clin Psychiatry. 2003 Jul; 64(7):799-806.
-
Linnebur SA, Saseen JJ, Pace WD. Venlafaxine-associated vaginal bleeding. Pharmacotherapy. 2002 May; 22(5):652-5.
-
Little JT, Ketter TA, Kimbrell TA, Danielson A, Benson B, Willis MW, Post RM. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol Bull. 1996; 32(4):629-35.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|